Biosimilars Regulatory Roundup for August 2022—Podcast Edition
Season 5, Episode 5, Sep 04, 2022, 11:00 AM
On this episode of Not So Different, we look back at some of the biggest regulatory events to happen in the biosimilar space during August, including 2 European approvals, 2 US approvals, and the advancement of the Inflation Reduction Act of 2022.
Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics
https://www.centerforbiosimilars.com/view/opinion-impact-of-inflation-reduction-act-2022-addressing-critics
https://www.centerforbiosimilars.com/view/opinion-impact-of-inflation-reduction-act-2022-addressing-critics
Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition
https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition
https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition
$35 Insulin Cap for Private Sector Blocked From Budget Reconciliation Bill
https://www.centerforbiosimilars.com/view/-35-insulin-cap-for-private-sector-blocked-from-budget-reconciliation-bill
https://www.centerforbiosimilars.com/view/-35-insulin-cap-for-private-sector-blocked-from-budget-reconciliation-bill
European Commission Approves Second Lucentis Biosimilar
https://www.centerforbiosimilars.com/view/european-commission-approves-second-lucentis-biosimilar
https://www.centerforbiosimilars.com/view/european-commission-approves-second-lucentis-biosimilar
FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab
https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab
https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab
FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
Eye on Pharma: Celltrion Aims for Adalimumab Interchangeability; Phase 3 Results for Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase-3-results-for-ustekinumab-biosimilar
https://www.centerforbiosimilars.com/view/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase-3-results-for-ustekinumab-biosimilar
EC Grants Celltrion Avastin Biosimilar Marketing Authorization
https://www.centerforbiosimilars.com/view/ec-grants-celltrion-avastin-biosimilar-marketing-authorization
https://www.centerforbiosimilars.com/view/ec-grants-celltrion-avastin-biosimilar-marketing-authorization
BLA Accepted for Fresenius Kabi Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/bla-accepted-for-fresenius-kabi-tocilizumab-biosimilar
https://www.centerforbiosimilars.com/view/bla-accepted-for-fresenius-kabi-tocilizumab-biosimilar